For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis advises that on July 4, 2014 it received a notice from NovaQuest Capital Management, an affiliate of NovaQuest Pharma Opportunities Fund III, L.P. (“NovaQuest”), alleging Pharmaxis has breached the Financing Agreement, dated January 30, 2013, between the Company and NovaQuest and that an event of default will occur on August 3, 2014.
The Company strongly rejects the allegation it is in breach, will contest the allegation and take all appropriate steps to ensure that NovaQuest complies fully with its obligations under the Financing Agreement.Read full media release - pdf
Pharmaceutical development company Pharmaxis is pleased to announce that its product for cystic fibrosis, Bronchitol, has been shortlisted for the prestigious UK Prix Galien Orphan Drug Award.
Prix Galien is an internationally-recognised award, providing global recognition for the technical, scientific and clinical research skills necessary to develop innovative medicines. Moreover, it gives pharmaceutical companies the opportunity to have their products scrutinised by some of the UK medical profession’s most eminent experts, and to be assessed according to the medical, societal and economic benefits they are likely to provide.
The UK Prix Galien judging team is led by Professor Sir Michael Rawlins, President of the Royal Society of Medicine and, until 2013, founding Chairman of the National Institute of Health and Care Excellence. Professor Rawlins is joined by a panel of influential stakeholders from the UK healthcare system.
Read full media release - pdf
Pharmaceutical development company Pharmaxis has completed a successful round of engagement at the European Cystic Fibrosis Conference (ECFC) in Gothenburg, Sweden, hosting eight sessions featuring the clinical and practical experience of key cystic fibrosis (CF) clinics with Bronchitol® and involving a global panel of key opinion leaders.Read full media release - pdf